Comprehensive overview of microRNA function in rheumatoid arthritis

Crowson, C. S. et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann. Rheum. Dis. 77, 48–54 (2018).

Safiri, S. et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann. Rheum. Dis. 78, 1463–1471 (2019).

Fu, J. et al. Shared epitope-aryl hydrocarbon receptor crosstalk underlies the mechanism of gene-environment interaction in autoimmune arthritis. Proc. Natl. Acad. Sci. USA 115, 4755–4760 (2018).

Ospelt, C. et al. Epigenetics in the pathogenesis of RA. Semin Immunopathol. 39, 409–419 (2017).

McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).

Scott, D. L. et al. Rheumatoid arthritis. Lancet 376, 1094–1108 (2010).

McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328–2337 (2017).

Lee, R. C. et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 (1993).

Bushati, N. & Cohen, S. M. microRNA functions. Annu Rev. Cell Dev. Biol. 23, 175–205 (2007).

Lee, Y. S. & Dutta, A. MicroRNAs in cancer. Annu Rev. Pathol. 4, 199–227 (2009).

Zhou, S. S. et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharm. Sin. 39, 1073–1084 (2018).

Ali, S. A. et al. The non-coding RNA interactome in joint health and disease. Nat. Rev. Rheumatol. 17, 692–705 (2021).

Dakin, S. G. et al. Pathogenic stromal cells as therapeutic targets in joint inflammation. Nat. Rev. Rheumatol. 14, 714–726 (2018).

Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. JAMA 320, 1360–1372 (2018).

Bottini, N. & Firestein, G. S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24–33 (2012).

Mousavi, M. J. et al. Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe. Auto. Immun. Highlights 12, 3 (2021).

Firestein, G. S. et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. USA 94, 10895–10900 (1997).

Tu, J. et al. A Tale of Two Immune Cells in Rheumatoid Arthritis: The Crosstalk Between Macrophages and T Cells in the Synovium. Front. Immunol. 12, 655477 (2021).

Kondo, Y. et al. Review: Transcriptional Regulation of CD4+ T Cell Differentiation in Experimentally Induced Arthritis and Rheumatoid Arthritis. Arthritis Rheumatol. 70, 653–661 (2018).

Niu, Q. et al. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol. Int. 32, 2731–2736 (2012).

Wehrens, E. J. et al. T cells out of control-impaired immune regulation in the inflamed joint. Nat. Rev. Rheumatol. 9, 34–42 (2013).

Wu, F. et al. B Cells in Rheumatoid ArthritisPathogenic Mechanisms and Treatment Prospects. Front. Immunol. 12, 750753 (2021).

Ronnelid, J. et al. Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. Front. Immunol. 12, 685312 (2021).

Kennedy, A. et al. Macrophages in synovial inflammation. Front. Immunol. 2, 52 (2011).

Hannemann, N. et al. New insights into macrophage heterogeneity in rheumatoid arthritis. Jt. Bone Spine 88, 105091 (2021).

Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792–804 (2013).

Lavin, Y. et al. Regulation of macrophage development and function in peripheral tissues. Nat. Rev. Immunol. 15, 731–744 (2015).

Huang, Q.-Q. et al. Critical role of synovial tissue-resident macrophage niche in joint homeostasis and suppression of chronic inflammation. Sci. Adv. 7, eabd0515 (2021).

Das, A. et al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am. J. Pathol. 185, 2596–2606 (2015).

Funes, S. C. et al. Implications of macrophage polarization in autoimmunity. Immunology 154, 186–195 (2018).

Wang, Y. et al. Is macrophage polarization important in rheumatoid arthritis? Int. Immunopharmacol. 50, 345–352 (2017).

Cascao, R. et al. Neutrophils in rheumatoid arthritis: More than simple final effectors. Autoimmun. Rev. 9, 531–535 (2010).

Iberg, C. A. et al. Dendritic cells as inducers of peripheral tolerance. Trends Immunol. 38, 793–804 (2017).

Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343–353 (2015).

Schett, G. & Gravallese, E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 8, 656–664 (2012).

Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 40, 251–264 (2007).

Wada, T. et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17–25 (2006).

Amarasekara, D. S. et al. Regulation of Osteoclast Differentiation by Cytokine Networks. Immune Netw. 18, e8 (2018).

Hashizume, M. et al. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatol. (Oxf.) 47, 1635–1640 (2008).

Baum, R. & Gravallese, E. M. Bone as a target organ in rheumatic disease: impact on osteoclasts and osteoblasts. Clin. Rev. Allergy Immunol. 51, 1–15 (2016).

Otero, M. & Goldring, M. B. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res. Ther. 9, 220 (2007).

Li, Z. et al. Omentin-1 prevents cartilage matrix destruction by regulating matrix metalloproteinases. Biomed. Pharmacother. 92, 265–269 (2017).

Goldring, M. B. & Marcu, K. B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res. Ther. 11, 224 (2009).

Falconer, J. et al. Review: synovial cell metabolism and chronic inflammation in rheumatoid arthritis. Arthritis Rheumatol. 70, 984–999 (2018).

Elshabrawy, H. A. et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18, 433–448 (2015).

Laurent, L. et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann. Rheum. Dis. 70, 1052–1059 (2011).

Negishi-Koga, T. et al. Immune complexes regulate bone metabolism through FcRgamma signalling. Nat. Commun. 6, 6637 (2015).

Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233–255 (2010).

Bottini, N. & Firestein, G. S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24–33 (2013).

Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509–524 (2014).

Chen, J. F. et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228–233 (2006).

Di Leva, G. et al. MicroRNAs in cancer. Annu. Rev. Pathol. 9, 287–314 (2014).

Krol, J. et al. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597–610 (2010).

Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016–3027 (2004).

Diederichs, S. & Haber, D. A. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 131, 1097–1108 (2007).

Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).

Wilson, R. C. & Doudna, J. A. Molecular mechanisms of RNA interference. Annu. Rev. Biophys. 42, 217–239 (2013).

Guo, H. et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835–840 (2010).

Friedman, R. C. et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105 (2009).

Alghamdi, M. et al. Circulating extracellular vesicles and rheumatoid arthritis: a proteomic analysis. Cell Mol. Life Sci. 79, 25 (2021).

Li, D. et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016).

van Niel, G. et al. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).

Zhu, S. et al. Coupling factors and exosomal packaging microRNAs involved in the regulation of bone remodelling. Biol. Rev. Camb. Philos. Soc. 93, 469–480 (2018).

Ji, C. & Guo, X. The clinical potential of circulating microRNAs in obesity. Nat. Rev. Endocrinol. 15, 731–743 (2019).

Kowal, J. et al. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 29, 116–125 (2014).

Garcia-Martin, R. et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature 601, 446–451 (2022).

Villarroya-Beltri, C. et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 4, 2980 (2013).

Santangelo, L. et al. The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. Cell Rep. 17, 799–808 (2016).

Hobor, F. et al. A cryptic RNA-binding domain mediates Syncrip recognition and exosomal partitioning of miRNA targets. Nat. Commun. 9, 831 (2018).

Teng, Y. et al. MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat. Commun. 8, 14448 (2017).

Mukherjee, K. et al. Reversible HuR-microRNA binding controls extracellular export of miR-122 and augments stress response. EMBO Rep. 17, 1184–1203 (2016).

Shurtleff, M. J. et al. Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. Elife 5, e19276 (2016).

Liu, X. M. et al. Selective sorting of microRNAs into exosomes by phase-separated YBX1 condensates. Elife 10, e71982 (2021).

Koppers-Lalic, D. et al. Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 8, 1649–1658 (2014).

Gibbings, D. J. et al. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 11, 1143–1149 (2009).

McKenzie, A. J. et al. KRAS-MEK signaling controls Ago2 sorting into Exosomes. Cell Rep. 15, 978–987 (2016).

Guduric-Fuchs, J. et al. Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genom. 13, 357 (2012).

Git, A. et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 16, 991–1006 (2010).

Correia de Sousa M. et al. Deciphering miRNAs’ Action through miRNA Editing. Int. J. Mol. Sci. 20, 6249 (2019).

Stanczyk, J. et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 58, 1001–1009 (2008).

Xie, Z. et al. PU.1 attenuates TNFalphainduced proliferation and cytokine release of rheumatoid arthritis fibroblastlike synoviocytes by regulating miR155 activity. Mol. Med. Rep. 17, 8349–8356 (2018).

Liu, N. et al. Paeonol protects against TNF-alpha-induced proliferation and cytokine release of rheumatoid arthritis fibroblast-like synoviocytes by upregulating FOXO3 through inhibition of miR-155 expression. Inflamm. Res. 66, 603–610 (2017).

Long, L. et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin. Dev. Immunol. 2013, 296139 (2013).

Saferding, V. et al. MicroRNA-146a governs fibroblast activation and joint pathology in arthritis. J. Autoimmun. 82, 74–84 (2017).

Sun, W. et al. Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA-146a-5p in rheumatoid arthritis. Arthritis Res. Ther. 22, 61 (2020).

Hong, B. K. et al. MicroRNA-143 and -145 modulate the phenotype of synovial fibroblasts in rheumatoid arthritis. Exp. Mol. Med. 49, e363 (2017).

Wang, X. et al. Elevated microRNA1455p increases matrix metalloproteinase9 by activating the nuclear factorkappaB pathway in rheumatoid arthritis. Mol. Med. Rep. 20, 2703–2711 (2019).

Huang, Z. et al. MiR-26a-5p enhances cells proliferation, invasion, and apoptosis resistance of fibroblast-like synoviocytes in rheumatoid arthritis by regulating PTEN/PI3K/AKT pathway. Biosci. Rep. 39, BSR20182192 (2019).

Chen, Y. et al. MicroRNA-21 Promotes Proliferation of Fibroblast-Like Synoviocytes through Mediation of NF-kappaB Nuclear Translocation in a Rat Model of Collagen-Induced Rheumatoid Arthritis. Biomed. Res. Int. 2016, 9279078 (2016).

Stanczyk, J. et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 63, 373–381 (2011).

Pandis, I. et al. Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model. Ann. Rheum. Dis. 71, 1716–1723 (2012).

Alsaleh, G. et al. Bruton’s tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J. Immunol. 182, 5088–5097 (2009).

Najm, A. et al. MicroRNA-17-5p reduces inflammation and bone erosions in mice with collagen-induced arthritis and directly targets the JAK/STAT pathway in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol. 72, 2030–2039 (2020).

Lin, J. et al. A novel p53/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis. Arthritis Rheumatol. 66, 49–59 (2014).

Nakamachi, Y. et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 60, 1294–1304 (2009).

Kawano, S. & Nakamachi, Y. miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, i88–i91 (2011).

Zhou, Q. et al. Research of the methylation status of miR-124a gene promoter among rheumatoid arthritis patients. Clin. Dev. Immunol. 2013, 524204 (2013).

Zhou, Q. et al. Demethylation of microRNA-124a genes attenuated proliferation of rheumatoid arthritis derived fibroblast-like synoviocytes and synthesis of tumor necrosis factor-alpha. PLoS One 11, e0164207 (2016).

Wang, J. et al. Identification of a novel microRNA-141-3p/Forkhead box C1/beta-catenin axis associated with rheumatoid arthritis synovial fibroblast function in vivo and in vitro. Theranostics 10, 5412–5434 (2020).

Liu, L. et al. MicroRNA-106b Overexpression suppresses synovial inflammation and alleviates synovial damage in patients with rheumatoid arthritis. Mod. Rheumatol. 32, 1054–1063 (2021).

Lee, W. S. et al. MicroRNA-9 ameliorates destructive arthritis through down-regulation of NF-kappaB1-RANKL pathway in fibroblast-like synoviocytes. Clin. Immunol. 212, 108348 (2020).

Philippe, L. et al. TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J. Immunol. 188, 454–461 (2012).

Shi, D. L. et al. MicroRNA-27a inhibits cell migration and invasion of fibroblast-like synoviocytes by targeting follistatin-like protein 1 in rheumatoid arthritis. Mol. Cells 39, 611–618 (2016).

Liu, J. et al. MicroRNA-29a inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by repressing STAT3. Biomed. Pharmacother. 96, 173–181 (2017).

Li, S. et al. MicroRNA-192 suppresses cell proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes by downregulating caveolin 1. Mol. Cell Biochem. 432, 123–130 (2017).

Wangyang, Y. et al. MiR-199a-3p inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via suppressing retinoblastoma 1. Biosci. Rep. 38, BSR20180982 (2018).

Miao, C. G. et al. miR-375 regulates the canonical Wnt pathway through FZD8 silencing in arthritis synovial fibroblasts. Immunol. Lett. 164, 1–10 (2015).

Song, A. F. et al. MiR-34a-5p inhibits fibroblastlike synoviocytes proliferation via XBP1. Eur. Rev. Med. Pharm. Sci. 24, 11675–11682 (2020).

Wu, H. et al. miR-34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis. J. Cell Mol. Med. 25, 1896–1910 (2021).

Wei, H. et al. MicroRNA-15a/16/SOX5 axis promotes migration, invasion and inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Aging (Albany NY) 12, 14376–14390 (2020).

Fu, D. et al. MiR-3926 inhibits synovial fibroblasts proliferation and inflammatory cytokines secretion through targeting toll like receptor 5. Gene 687, 200–206 (2019).

Xie, Z. et al. MiR-20a inhibits the progression of human arthritis fibroblast-like synoviocytes and inflammatory factor expression by targeting ADAM10. Environ. Toxicol. 35, 867–878 (2020).

Baltimore, D. et al. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9, 839–845 (2008).

Cobos Jimenez, V. et al. Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol. Genom. 46, 91–103 (2014).

Paoletti, A. et al. Monocyte/macrophage abnormalities specific to rheumatoid arthritis are linked to miR-155 and are differentially modulated by different TNF inhibitors. J. Immunol. 203, 1766–1775 (2019).

Xu, J. et al. NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J. Clin. Investig. 125, 1579–1590 (2015).

Huang, C. et al. MiR-146a modulates macrophage polarization by inhibiting Notch1 pathway in RAW264.7 macrophages. Int Immunopharmacol. 32, 46–54 (2016).

O’Connell, R. M. et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. USA 104, 1604–1609 (2007).

Taganov, K. D. et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12481–12486 (2006).

Mann, M. et al. An NF-kappaB-microRNA regulatory network tunes macrophage inflammatory responses. Nat. Commun. 8, 851 (2017).

Du, F. et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb. Vasc. Biol. 34, 759–767 (2014).

Schulte, L. N. et al. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res. 41, 542–553 (2013).

Nakasa, T. et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 63, 1582–1590 (2011).

Rajasekhar, M. et al. MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis. J. Autoimmun. 79, 53–62 (2017).

Elmesmari, A. et al. MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. Rheumatol. (Oxf.) 55, 2056–2065 (2016).

Kurowska-Stolarska, M. et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl. Acad. Sci. USA 108, 11193–11198 (2011).

Ghani, S. et al. Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood 118, 2275–2284 (2011).

Chan, E. K. et al. MicroRNA-146a in autoimmunity and innate immune responses. Ann. Rheum. Dis. 72, ii90–ii95 (2013).

Ammari, M. et al. Delivery of miR-146a to Ly6C(high) Monocytes Inhibits Pathogenic Bone Erosion in Inflammatory Arthritis. Theranostics 8, 5972–5985 (2018).

Chen, Q. et al. Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1beta production in macrophages by targeting STAT3. PLoS One 7, e42971 (2012).

Xue, Y. L. et al. Long non-coding RNA MEG3 inhibits M2 macrophage polarization by activating TRAF6 via microRNA-223 down-regulation in viral myocarditis. J. Cell Mol. Med. 24, 12341–12354 (2020).

Zhuang, G. et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 125, 2892–2903 (2012).

Zhang, Q. B. et al. MicroRNA-223 Suppresses IL-1beta and TNF-alpha Production in Gouty Inflammation by Targeting the NLRP3 Inflammasome. Front. Pharm. 12, 637415 (2021).

Ogando, J. et al. Notch-regulated miR-223 targets the aryl hydrocarbon receptor pathway and increases cytokine production in macrophages from rheumatoid arthritis patients. Sci. Rep. 6, 20223 (2016).

Quero, L. et al. MiR-221-3p drives the shift of M2-macrophages to a pro-Inflammatory function by suppressing JAK3/STAT3 activation. Front. Immunol. 10, 3087 (2019).

Banerjee, S. et al. MiR-125a-5p regulates differential activation of macrophages and inflammation. J. Biol. Chem. 288, 35428–35436 (2013).

Wang, W. & Guo, Z. H. Downregulation of lncRNA NEAT1 ameliorates LPS-induced inflammatory responses by promoting macrophage M2 polarization via miR-125a-5p/TRAF6/TAK1 axis. Inflammation 43, 1548–1560 (2020).

Zhou, G. et al. Role and mechanism of miR-144-5p in LPS-induced macrophages. Exp. Ther. Med. 19, 241–247 (2020).

Zhu, D. et al. MicroRNA-17/20a/106a modulate macrophage inflammatory responses through targeting signal-regulatory protein alpha. J. Allergy Clin. Immunol. 132, 426–436.e428 (2013).

Jo, E. K. et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol. Immunol. 13, 148–159 (2016).

Bai, B. et al. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 11, 776 (2020).

Choulaki, C. et al. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res. Ther. 17, 257 (2015).

Zhang, Y. et al. NLRP3 inflammasome plays an important role in the pathogenesis of collagen-induced arthritis. Mediators Inflamm. 2016, 9656270 (2016).

Guo, C. et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin. Exp. Immunol. 194, 231–243 (2018).

Xie, Q. et al. MicroRNA33 regulates the NLRP3 inflammasome signaling pathway in macrophages. Mol. Med. Rep. 17, 3318–3327 (2018).

Yang, Q. et al. RelA/MicroRNA-30a/NLRP3 signal axis is involved in rheumatoid arthritis via regulating NLRP3 inflammasome in macrophages. Cell Death Dis. 12, 1060 (2021).

Lai, N. S. et al. Anti-citrullinated protein antibodies suppress let-7a expression in monocytes from patients with rheumatoid arthritis and facilitate the inflammatory responses in rheumatoid arthritis. Immunobiology 220, 1351–1358 (2015).

Zhu, W. et al. MiR-let-7a regulates anti-citrullinated protein antibody-induced macrophage activation and correlates with the development of experimental rheumatoid arthritis. Int. Immunopharmacol. 51, 40–46 (2017).

Kim, S. J. et al. Identification of a novel toll-like receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation. Arthritis Rheumatol. 68, 1099–1110 (2016).

Banerjee, A. et al. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur. J. Immunol. 40, 225–231 (2010).

Jiang, S. et al. Molecular dissection of the miR-17-92 cluster’s critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118, 5487–5497 (2011).

Steiner, D. F. et al. MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. Immunity 35, 169–181 (2011).

Dong, L. et al. Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J. Cell Mol. Med. 18, 2213–2224 (2014).

Escobar, T. M. et al. MiR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity 40, 865–879 (2014).

Lu, L. F. et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30, 80–91 (2009).

Hippen, K. L. et al. Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front. Immunol. 9, 57 (2018).

Kmiolek, T. et al. The Interplay between Transcriptional Factors and MicroRNAs as an Important Factor for Th17/Treg Balance in RA Patients. Int. J. Mol. Sci. 21, 7169 (2020).

Zhou, Q. et al. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann. Rheum. Dis. 74, 1265–1274 (2015).

Lu, L. F. et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142, 914–929 (2010).

Tang, X. et al. Correlation between the expression of microRNA-301a-3p and the proportion of th17 cells in patients with rheumatoid arthritis. Inflammation 39, 759–767 (2016).

Korn, T. et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485–517 (2009).

Yang, P. et al. MicroRNA let-7g-5p alleviates murine collagen-induced arthritis by inhibiting Th17 cell differentiation. Biochem. Pharm. 174, 113822 (2020).

Di, Y. et al. Catalpol inhibits tregs-to-Th17 cell transdifferentiation by up-regulating let-7g-5p to reduce STAT3 protein levels. Yonsei Med. J. 63, 56–65 (2022).

Zhang, M. F. et al. MicroRNA-26b-5p alleviates murine collagen-induced arthritis by modulating Th17 cell plasticity. Cell Immunol. 365, 104382 (2021).

Xie, M. et al. NF-kappaB-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3. J. Autoimmun. 102, 96–113 (2019).

Jin, S. et al. Protectin DX restores Treg/Th17 cell balance in rheumatoid arthritis by inhibiting NLRP3 inflammasome via miR-20a. Cell Death Dis. 12, 280 (2021).

Jin, S. et al. Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21. Ann. Rheum. Dis. 77, 1644–1652 (2018).

Wu, Y. H. et al. Upregulated Expression of microRNA-16 Correlates with Th17/Treg Cell Imbalance in Patients with Rheumatoid Arthritis. DNA Cell Biol. 35, 853–860 (2016).

Lu, J. et al. Follicular helper T cells: potential therapeutic targets in rheumatoid arthritis. Cell Mol. Life Sci. 78, 5095–5106 (2021).

Pratama, A. et al. MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. Nat. Commun. 6, 6436 (2015).

Liu, W. H. et al. A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. J. Exp. Med. 213, 1901–1919 (2016).

Hu, R. et al. miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. Immunity 41, 605–619 (2014).

Alivernini, S. et al. MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nat. Commun. 7, 12970 (2016).

Heinicke, F. et al. MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients. Front. Immunol. 12, 663736 (2021).

Pan, F. et al. Dendritic Cells from Rheumatoid Arthritis Patient Peripheral Blood Induce Th17 Cell Differentiation via miR-363/Integrin alphav/TGF-beta Axis. Scand. J. Immunol. 85, 441–449 (2017).

Kurowska-Stolarska, M. et al. MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nat. Commun. 8, 15877 (2017).

De la Rosa, I. A. et al. Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies. Haematologica 105, 2250–2261 (2020).

Murata, K. et al. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheumatol. 66, 549–559 (2014).

Lian, J. B. et al. MicroRNA control of bone formation and homeostasis. Nat. Rev. Endocrinol. 8, 212–227 (2012).

Mizoguchi, F. et al. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J. Cell Biochem. 109, 866–875 (2010).

Wang, T. et al. MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone. Oncotarget 6, 18980–18996 (2015).

Kong, X. H. et al. MicroRNA-20a suppresses RANKL-modulated osteoclastogenesis and prevents bone erosion in mice with rheumatoid arthritis through the TLR4/p38 pathway. J. Biol. Regul. Homeost. Agents 35, 921–931 (2021).

Tao, Y. et al. Downregulation of miR-106b attenuates inflammatory responses and joint damage in collagen-induced arthritis. Rheumatol. (Oxf.) 56, 1804–1813 (2017).

Guo, L. J. et al. MiR-125a TNF receptor-associated factor 6 to inhibit osteoclastogenesis. Exp. Cell Res. 321, 142–152 (2014).

Liu, K. et al. MiR-125 regulates PI3K/Akt/mTOR signaling pathway in rheumatoid arthritis rats via PARP2. Biosci. Rep. 39, BSR20180890 (2019).

Jiang, B. et al. MiR-143-3p inhibits the differentiation of osteoclast induced by synovial fibroblast and monocyte coculture in adjuvant-induced arthritic rats. Biomed. Res. Int. 2021, 5565973 (2021).

de la Rica, L. et al. NF-kappaB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation. Genome Biol. 16, 2 (2015).

Donate, P. B. et al. Cigarette smoke induces miR-132 in Th17 cells that enhance osteoclastogenesis in inflammatory arthritis. Proc. Natl. Acad. Sci. USA 118, e2017120118 (2021).

Lee, Y. et al. MicroRNA-124 regulates osteoclast differentiation. Bone 56, 383–389 (2013).

Nakamachi, Y. et al. MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats. Ann. Rheum. Dis. 75, 601–608 (2016).

Pauley, K. M. & Cha, S. MiRNA-146a in rheumatoid arthritis: a new therapeutic strategy. Immunotherapy 3, 829–831 (2011).

Chen, Y. et al. MiR-145-5p increases osteoclast numbers in vitro and aggravates bone erosion in collagen-induced arthritis by targeting osteoprotegerin. Med. Sci. Monit. 24, 5292–5300 (2018).

Noack, M. & Miossec, P. Selected cytokine pathways in rheumatoid arthritis. Semin. Immunopathol. 39, 365–383 (2017).

Ohnuma, K. et al. MicroRNA-124 inhibits TNF-alpha- and IL-6-induced osteoclastogenesis. Rheumatol. Int. 39, 689–695 (2019).

Miller, C. H. et al. RBP-J-regulated miR-182 promotes TNF-alpha-induced osteoclastogenesis. J. Immunol. 196, 4977–4986 (2016).

Sun, Y. et al. Recent advances in osteoclast biological behavior. Front. Cell Dev. Biol. 9, 788680 (2021).

Wang, T. et al. Proteus mirabilis Vesicles Induce Mitochondrial Apoptosis by Regulating miR96-5p/Abca1 to Inhibit Osteoclastogenesis and Bone Loss. Front. Immunol. 13, 833040 (2022).

Maeda, Y. et al. Synovium-derived microRNAs regulate bone pathways in rheumatoid arthritis. J. Bone Min. Res. 32, 461–472 (2017).

Hassan, M. Q. et al. MiR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 287, 42084–42092 (2012).

Iwamoto, N. et al. Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway. Arthritis Res. Ther. 20, 189 (2018).

Yang, W. H. et al. Leptin induces oncostatin M production in osteoblasts by downregulating miR-93 through the Akt signaling pathway. Int. J. Mol. Sci. 15, 15778–15790 (2014).

Tsai, C. H. et al. Osteopontin inhibition of miR-129-3p enhances IL-17 expression and monocyte migration in rheumatoid arthritis. Biochim. Biophys. Acta Gen. Subj. 1861, 15–22 (2017).

Li, T. M. et al. YKL-40-induced inhibition of miR-590-3p promotes interleukin-18 expression and angiogenesis of endothelial progenitor cells. Int. J. Mol. Sci. 18, 920 (2017).

Kusumbe, A. P. et al. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323–328 (2014).

Chen, C. Y. et al. CCN1 promotes VEGF production in osteoblasts and induces endothelial progenitor cell angiogenesis by inhibiting miR-126 expression in rheumatoid arthritis. J. Bone Min. Res. 32, 34–45 (2017).

Chen, C. Y. et al. Enhancement of CCL2 expression and monocyte migration by CCN1 in osteoblasts through inhibiting miR-518a-5p: implication of rheumatoid arthritis therapy. Sci. Rep. 7, 421 (2017).

Huang, C. C. et al. S1P Increases VEGF production in osteoblasts and facilitates endothelial progenitor cell angiogenesis by inhibiting miR-16-5p expression via the c-Src/FAK signaling pathway in rheumatoid arthritis. Cells 10, 2168 (2021).

Chen, Y. J. et al. Systematic analysis of differential expression profile in rheumatoid arthritis chondrocytes using next-generation sequencing and bioinformatics approaches. Int. J. Med. Sci. 15, 1129–1142 (2018).

Zhuo, Q. et al. LncRNA ZNF667-AS1 alleviates rheumatoid arthritis by sponging miR-523-3p and inactivating the JAK/STAT signalling pathway. Autoimmunity 54, 406–414 (2021).

Zhang, H. J. et al. LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-kappaB pathway. Int. Immunopharmacol. 50, 283–290 (2017).

Li, G. et al. LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway. J. Cell Mol. Med. 23, 7116–7120 (2019).

Hu, J. et al. MiR-23a inhibited IL-17-mediated proinflammatory mediators expression via targeting IKKalpha in articular chondrocytes. Int. Immunopharmacol. 43, 1–6 (2017).

Li, G. et al. circFADS2 protects LPS-treated chondrocytes from apoptosis acting as an interceptor of miR-498/mTOR cross-talking. Aging (Albany NY) 11, 3348–3361 (2019).

Zhou, Y. et al. MicroRNA-27b-3p inhibits apoptosis of chondrocyte in rheumatoid arthritis by targeting HIPK2. Artif. Cells Nanomed. Biotechnol. 47, 1766–1771 (2019).

Jiang, L. & Cao, S. Role of microRNA-26a in cartilage injury and chondrocyte proliferation and apoptosis in rheumatoid arthritis rats by regulating expression of CTGF. J. Cell Physiol. 235, 979–992 (2020).

Miyaki, S. et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 24, 1173–1185 (2010).

Si, H. B. et al. MiR-140 attenuates the progression of early-stage osteoarthritis by retarding chondrocyte senescence. Mol. Ther. Nucleic Acids 19, 15–30 (2020).

Wang, Z. et al. MiR-140-5p/miR-149 affects chondrocyte proliferation, apoptosis, and autophagy by targeting FUT1 in osteoarthritis. Inflammation 41, 959–971 (2018).

Li, X. et al. MiR-29a and MiR-140 Protect Chondrocytes against the Anti-Proliferation and Cell Matrix Signaling Changes by IL-1beta. Mol. Cells 39, 103–110 (2016).

Li, H. et al. MiR-140-5p inhibits synovial fibroblasts proliferation and inflammatory cytokines secretion through targeting TLR4. Biomed. Pharmacother. 96, 208–214 (2017).

Chen, J. et al. Exosomal miRNA-486-5p derived from rheumatoid arthritis fibroblast-like synoviocytes induces osteoblast differentiation through the Tob1/BMP/Smad pathway. Biomater. Sci. 8, 3430–3442 (2020).

Liu, D. et al. Synovial fibroblast-derived exosomal microRNA-106b suppresses chondrocyte proliferation and migration in rheumatoid arthritis via down-regulation of PDK4. J. Mol. Med. (Berl.) 98, 409–423 (2020).

Ding, Y. et al. Exosomes derived from synovial fibroblasts under hypoxia aggravate rheumatoid arthritis by regulating Treg/Th17 balance. Exp. Biol. Med. (Maywood) 245, 1177–1186 (2020).

Meng, Q. & Qiu, B. Exosomal microRNA-320a derived from mesenchymal stem cells regulates rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing CXCL9 expression. Front. Physiol. 11, 441 (2020).

Chen, Z. et al. Therapeutic potential of mesenchymal cell-derived miRNA-150-5p-expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. J. Immunol. 201, 2472–2482 (2018).

Meng, H. Y. et al. The inhibition by human MSCs-derived miRNA-124a overexpression exosomes in the proliferation and migration of rheumatoid arthritis-related fibroblast-like synoviocyte cell. BMC Musculoskelet. Disord. 21, 150 (2020).

Huang, Y. et al. Exosomal microRNA-140-3p from human umbilical cord mesenchymal stem cells attenuates joint injury of rats with rheumatoid arthritis by silencing SGK1. Mol. Med. 28, 36 (2022).

Tavasolian, F. et al. MiRNA-146a improves immunomodulatory effects of MSC-derived exosomes in rheumatoid arthritis. Curr. Gene Ther. 20, 297–312 (2020).

Wu, L. F. et al. Identification of novel rheumatoid arthritis-associated MiRNA-204-5p from plasma exosomes. Exp. Mol. Med. 54, 334–345 (2022).

Vickers, K. C. et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433 (2011).

Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 108, 5003–5008 (2011).

Lindner, K. et al. Circulating microRNAs: emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers. Clin. Sci. (Lond.) 128, 1–15 (2015).

Luque-Tevar, M. et al. Integrative clinical, molecular, and computational analysis identify novel biomarkers and differential profiles of anti-TNF response in rheumatoid arthritis. Front. Immunol. 12, 631662 (2021).

Taha, M. et al. Serum a proliferation-inducing ligand and MicroRNA-223 are associated with rheumatoid arthritis: diagnostic and prognostic implications. Mol. Med. 26, 92 (2020).

Filkova, M. et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 73, 1898–1904 (2014).

Ouboussad, L. et al. Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis. Arthritis Res. Ther. 19, 288 (2017).

Cunningham, C. C. et al. Serum miRNA Signature in Rheumatoid Arthritis and “At-Risk Individuals”. Front. Immunol. 12, 633201 (2021).

Anaparti, V. et al. Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects. Arthritis Res. Ther. 19, 249 (2017).

Tang, J. et al. Identification of circulating miR-22-3p and let-7a-5p as novel diagnostic biomarkers for rheumatoid arthritis. Clin. Exp. Rheumatol. 40, 69–77 (2022).

Safari, F. et al. Plasma levels of microRNA-146a-5p, microRNA-24-3p, and microRNA-125a-5p as potential diagnostic biomarkers for rheumatoid arthris. Iran. J. Allergy Asthma Immunol. 20, 326–337 (2021).

Ormseth, M. J. et al. Utility of select plasma microRNA for disease and cardiovascular risk assessment in patients with rheumatoid arthritis. J. Rheumatol. 42, 1746–1751 (2015).

Liu, X. et al. Circulating microRNA-23b as a new biomarker for rheumatoid arthritis. Gene 712, 143911 (2019).

Kolarz, B. et al. Hypermethylation of the miR-155 gene in the whole blood and decreased plasma level of miR-155 in rheumatoid arthritis. PLoS ONE 15, e0233897 (2020).

Abdul-Maksoud, R. S. et al. Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis. Br. J. Biomed. Sci. 74, 209–213 (2017).

Wang, Y. et al. MiR-548a-3p regulates inflammatory response via TLR4/NF-kappaB signaling pathway in rheumatoid arthritis. J. Cell Biochem. 120, 1133–1140 (2018).

Xu, D. et al. Exosome-encapsulated miR-6089 regulates inflammatory response via targeting TLR4. J. Cell Physiol. 234, 1502–1511 (2019).

Rodriguez-Muguruza, S. et al. A serum biomarker panel of exomiR-451a, exomiR-25-3p and soluble TWEAK for early diagnosis of rheumatoid arthritis. Front. Immunol. 12, 790880 (2021).

Ormseth, M. J. et al. Development and validation of a microRNA panel to differentiate between patients with rheumatoid arthritis or systemic lupus erythematosus and controls. J. Rheumatol. 47, 188–196 (2020).

Jin, F. et al. Serum microRNA profiles serve as novel biomarkers for autoimmune diseases. Front. Immunol. 9, 2381 (2018).

Zhang, H. et al. B Cell-Related circulating microRNAs with the potential value of biomarkers in the differential diagnosis, and distinguishment between the disease activity and lupus nephritis for systemic lupus erythematosus. Front. Immunol. 9, 1473 (2018).

Cheleschi, S. et al. Circulating mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study. Transl. Res. 239, 18–34 (2022).

Murata, K. et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 12, R86 (2010).

Duroux-Richard, I. et al. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm. 2014, 342524 (2014).

Ciechomska, M. et al. Comprehensive microRNA and transcriptomic profiling of rheumatoid arthritis monocytes: role of microRNA-146b in pro-inflammatory progression. Rheumatol. (Oxf.) 60, 5424–5435 (2021).

Bae, S. C. & Lee, Y. H. MiR-146a levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Int. J. Rheum. Dis. 21, 1335–1342 (2018).

Li, Z. et al. Role of miR-9-5p in preventing peripheral neuropathy in patients with rheumatoid arthritis by targeting REST/miR-132 pathway. Vitr. Cell Dev. Biol. Anim. 55, 52–61 (2019).

Oka, S. et al. Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease. BMC Musculoskelet. Disord. 18, 21 (2017).

Ormseth, M. J. et al. Plasma miRNAs improve the prediction of coronary atherosclerosis in patients with rheumatoid arthritis. Clin. Rheumatol. 40, 2211–2219 (2021).

Liao, T. L. et al. Rituximab May Cause Increased Hepatitis C Virus Viremia in Rheumatoid Arthritis Patients Through Declining Exosomal MicroRNA-155. Arthritis Rheumatol. 70, 1209–1219 (2018).

Hruskova, V. et al. MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Arthritis Res. Ther. 18, 124 (2016).

Singh, A. et al. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis. Clin. Rheumatol. 38, 877–884 (2019).

Castro-Villegas, C. et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis Res. Ther. 17, 49 (2015).

Krintel, S. B. et al. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenom. J. 16, 141–146 (2016).

Sode, J. et al. Plasma microRNA profiles in patients with early rheumatoid arthritis responding to adalimumab plus methotrexate vs methotrexate alone: a placebo-controlled clinical trial. J. Rheumatol. 45, 53–61 (2018).

Ciechomska, M. et al. Changes in miRNA-5196 expression as a potential biomarker of anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis patients. Arch. Immunol. Ther. Exp. (Warsz.) 66, 389–397 (2018).

Liu, Y. et al. Correlation of microRNA expression profile with clinical response to tumor necrosis factor inhibitor in treating rheumatoid arthritis patients: A prospective cohort study. J. Clin. Lab. Anal. 33, e22953 (2019).

Fernandez-Ruiz, J. C. et al. Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment. Int Immunopharmacol. 63, 35–42 (2018).

Nasonov, E. et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann. Rheum. Dis. 81, 469–479 (2022).

Bure, I. V. et al. Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment. J. Pers. Med. 10, 205 (2020).

Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 2338–2348 (2017).

Guo, Q. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 6, 15 (2018).

Iwamoto, N. et al. Methotrexate alters the expression of microRNA in fibroblast-like synovial cells in rheumatoid arthritis. Int. J. Mol. Sci. 22, 11561 (2021).

Ren, B. et al. TNF-alpha-elicited miR-29b potentiates resistance to apoptosis in peripheral blood monocytes from patients with rheumatoid arthritis. Apoptosis 24, 892–904 (2019).

Zisman, D. et al. Tocilizumab (TCZ) decreases angiogenesis in rheumatoid arthritis through its regulatory effect on miR-146a-5p and EMMPRIN/CD147. Front. Immunol. 12, 739592 (2021).

Hayakawa, K. et al. MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-kappaB Signaling. Int. J. Mol. Sci. 20, 809 (2019).

Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Disco. 16, 203–222 (2017).

Ong, S. M. et al. MicroRNA-mediated immune modulation as a therapeutic strategy in host-implant integration. Adv. Drug Deliv. Rev. 88, 92–107 (2015).

Wu, J. et al. miR-708-5p promotes fibroblast-like synoviocytes’ cell apoptosis and ameliorates rheumatoid arthritis by the inhibition of Wnt3a/beta-catenin pathway. Drug Des. Devel. Ther. 12, 3439–3447 (2018).

Peng, J. S. et al. Amelioration of experimental autoimmune arthritis through targeting of synovial fibroblasts by intraarticular delivery of microRNAs 140-3p and 140-5p. Arthritis Rheumatol. 68, 370–381 (2016).

Liu, H. et al. Therapeutic prospects of microRNAs carried by mesenchymal stem cells-derived extracellular vesicles in autoimmune diseases. Life Sci. 277, 119458 (2021).

Cosenza, S. et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics 8, 1399–1410 (2018).

Zheng, J. et al. Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis. Int. Immunopharmacol. 78, 105985 (2020).

Li, G. Q. et al. MicroRNA-21 from bone marrow mesenchymal stem cell-derived extracellular vesicles targets TET1 to suppress KLF4 and alleviate rheumatoid arthritis. Ther. Adv. Chronic Dis. 12, 20406223211007369 (2021).

Huang, Y. et al. miR-223 in exosomes from bone marrow mesenchymal stem cells ameliorates rheumatoid arthritis via downregulation of NLRP3 expression in macrophages. Mol. Immunol. 143, 68–76 (2022).

You, D. G. et al. Metabolically engineered stem cell-derived exosomes to regulate macrophage heterogeneity in rheumatoid arthritis. Sci. Adv. 7, eabe0083 (2021).

Wiklander, O. P. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesic. 4, 26316 (2015).

Lv, H. et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release 114, 100–109 (2006).

Sujitha, S. et al. Berberine encapsulated PEG-coated liposomes attenuate Wnt1/beta-catenin signaling in rheumatoid arthritis via miR-23a activation. Eur. J. Pharm. Biopharm. 149, 170–191 (2020).

Hao, F. et al. Hybrid micelles containing methotrexate-conjugated polymer and co-loaded with microRNA-124 for rheumatoid arthritis therapy. Theranostics 9, 5282–5297 (2019).

Yu, C. et al. Ketoprofen and MicroRNA-124 Co-loaded poly (lactic-co-glycolic acid) microspheres inhibit progression of Adjuvant-induced arthritis in rats. Int J. Pharm. 552, 148–153 (2018).

Zhao, M. et al. Polyketal nanoparticles co-loaded with miR-124 and ketoprofen for treatment of rheumatoid arthritis. J. Pharm. Sci. 110, 2233–2240 (2021).

Zhang, X. et al. Efficient delivery of triptolide plus a miR-30-5p inhibitor through the use of near infrared laser responsive or CADY modified mSNs for efficacy in rheumatoid arthritis therapeutics. Front. Bioeng. Biotechnol. 8, 170 (2020).

Deng, Y. et al. Inflammation‐instructed hierarchical delivery of IL‐4/miR‐21 orchestrates osteoimmune microenvironment toward the treatment of rheumatoid arthritis. Adv. Funct. Mater. 31, 2101033 (2021).

Churov, A. V. et al. MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun. Rev. 14, 1029–1037 (2015).

Akhtar, N. et al. MicroRNA-17 suppresses TNF-alpha signaling by interfering with TRAF2 and cIAP2 association in rheumatoid arthritis synovial fibroblasts. J. Immunol. 197, 2219–2228 (2016).

Guggino, G. et al. Downregulation of miRNA17-92 cluster marks Vgamma9Vdelta2 T cells from patients with rheumatoid arthritis. Arthritis Res. Ther. 20, 236 (2018).